Drug Type Small molecule drug |
Synonyms CYRS 1645, CYRS1645, KNP-504 |
Target |
Mechanism SOS1 inhibitors(Son of sevenless homolog 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Cyrus Therapeutics, Inc.Startup |
Active Organization KANAPH Therapeutics, Inc.StartupCyrus Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 05 Jul 2024 |
Non-Small Cell Lung Cancer | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 05 Jul 2024 |
Pancreatic Ductal Adenocarcinoma | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 05 Jul 2024 |
Solid tumor | Preclinical | KR | Cyrus Therapeutics, Inc.Startup | 04 Jan 2024 |